Liver cancer

News

AZ claims another win for Imfinzi in frontline liver cancer

AstraZeneca has built the case for Imfinzi in earlier-stage liver cancer with a second phase 3 trial readout in its EMERALD programme.

News

AI predicts liver cancer risk with "high accuracy"

A machine learning algorithm could serve as a pre-screen for hepatocellular carcinoma that identifies patients missed by current narrow guidance.

News

MSD, Eisai abandon combination trial in liver cancer

MSD and Eisai's oncology partnership has had mixed fortunes this week, with a disappointment in liver cancer and encouraging data in kidney cancer.

Oncology

Interview at BIO 2025 with Pierre Arséne

Liver cancer diagnostic gets FDA breakthrough status, with P...

Mursla Bio CEO and founder Pierre Arséne discusses the breakthrough designation from the FDA for their blood test to catch liver cancer early.

News

BMS gets another FDA okay for Opdivo/Yervoy combo

Bristol-Myers Squibb has claimed its second FDA approval in just a few days for its Opdivo/Yervoy combination, this time in liver cancer.

News

BMS eyes April FDA verdict on Opdivo/Yervoy in liver cancer

The FDA has started a review of Bristol-Myers Squibb's immunotherapy duo Opdivo and Yervoy as a therapy for newly diagnosed unresectable liver cancer that could see a return to the category

AZ claims another win for Imfinzi in frontline liver cancer

AI predicts liver cancer risk with "high accuracy"

MSD, Eisai abandon combination trial in liver cancer

Liver cancer diagnostic gets FDA breakthrough status, with P...

BMS gets another FDA okay for Opdivo/Yervoy combo

BMS eyes April FDA verdict on Opdivo/Yervoy in liver cancer

OpenBind unveils its first AI model for drug discovery

Discover a new era of healthcare panel engagement: Grounded ...

Liver cancer

Editor's Picks